Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Aurobindo Pharma Gets Final Approvals For Quetiapine Fumarate Tablets

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients Aurobindo Pharma Ltd. announced that the company had obtained final approvals from the US Food & Drug Administration or US FDA to market Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg.

Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mgare the generic equivalent of AstraZeneca LP's Seroquel tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. These tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and fall under the Neurological (CNS) therapeutic category.

The company said the product had been approved out of Unit III facility in Hyderabad, India.

Aurobindo now has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals)from US FDA.

AT the BSE, Aurobindo Pharma shares are currently trading at Rs.116.55, up 1.66 percent from the previous close.

Click here to receive FREE breaking news email alerts for Aurobindo Pharma Ltd. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After reporting an unexpected drop in new orders for U.S. manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than expected in the month of June. After showing a lack of direction throughout much of the previous session, stocks may move to the downside in early trading on Friday. The major index futures are currently pointing to a modestly lower open for the markets, with the Dow futures down by 23 points. British economic growth remained high as expected in the second quarter as a robust expansion in the dominant service sector, and industry completely offset the slight weakness in the construction sector. With the second quarter expansion, GDP returned to its pre-crisis level. Gross domestic product grew 0.8 percent sequentially in the second quarter, the same rate as seen in the first quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.